Program
izalontamab brengitecan
Also written as “BL-B01D1”, “Iza-bren” and “BMS-986507”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Triple Negative Breast Neoplasms · Breast Neoplasms · Carcinoma, Transitional Cell, led by 2 companies.
Drug pageIzalontamab brengitecan: every studyAll 59 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Biokin Pharmaceuticalits history only | 5050 open or running | phase 3since Oct 25, 2023 | Jan 4, 2022 | Nov 2026phase 3 · NCT06118333 |
| Bristol-Myers Squibb | 55 open or running | phase 3since Apr 8, 2025 | Sep 26, 2024 | Mar 13, 2028phase 3 · NCT06926868 |
- Named in Bristol-Myers Squibb’s own pipeline as
iza-bren
, phase 3, as of Oct 29, 2026 (source).
Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseBristol Myers Squibb licensed it from SystImmune (Biokin), for outside mainland China, developed and sold jointly in the US.Announced Dec 11, 2023 · Source: SystImmune and Bristol Myers Squibb (release), Dec 11, 2023
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 6, 2023Named izalontamab brengitecanINNProposed as its International Nonproprietary Name in WHO's List 129 · before, BMS-986507
- Dec 11, 2023Bristol Myers Squibb licensed it from SystImmune (Biokin)LicenseOutside mainland China, developed and sold jointly in the US · announced · SystImmune and Bristol Myers Squibb (release)
- Sep 26, 2024First study: phase 2 study in Lung NeoplasmsFirst studyNCT06618287 · 416 planned · United States, Australia, Canada and more
- Apr 8, 2025Phase 3 study in Breast NeoplasmsNCT06926868 · 600 planned · United States, Argentina, Australia and more
- Jul 31, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07100080 · 661 planned · United States, Argentina, Belgium and more
- Aug 5, 2025Phase 3 study in Urinary Bladder NeoplasmsNCT07106762 · 470 planned · United States, Argentina, Australia and more
- Jun 26, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07680790 · 850 planned · United States, Argentina, Australia and more
Ahead
- Mar 13, 2028Primary completion: phase 3 study in Breast NeoplasmsNCT06926868
- Dec 15, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07100080
- Jan 26, 2029Primary completion: phase 3 study in Urinary Bladder NeoplasmsNCT07106762
- Feb 26, 2031Primary completion: phase 2 study in Lung NeoplasmsNCT06618287
TargetBeta
“A dual-targeted antibody-drug conjugate (ADC) consisting of a bispecific antibody directed against both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3) conjugated, via a cathepsin-B cleavable linker, to the camptothecin derivative …”NCIt, read by Claude
“A dual-targeted antibody-drug conjugate (ADC) consisting of a bispecific antibody directed against both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3) ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418rule | avenzo-therapeutics-inc | phase 2 | 1 |
| CS5007rule | CStone Pharmaceuticals | phase 1 | 1 |
Studies
All 5 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07680790Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Dec 30, 2031 | 850 |
| NCT07106762Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Jan 26, 2029 | 470 |
| NCT07100080Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more | 3 | Recruiting | Dec 15, 2028 | 661 |
| NCT06926868Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Mar 13, 2028 | 600 |
| NCT06618287Lung Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | Feb 26, 2031 | 416 |
How it is read
Names in the registry
- “BL-B01D1”, 49 entries
- “Iza-bren”, 4 entries
- “BMS-986507”, 1 entry
- “BL-B01D1 for Injection”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 15 studies
- Small Cell Lung Carcinoma, 4 studies
- Triple Negative Breast Neoplasms, 4 studies
- Breast Neoplasms, 4 studies
- Carcinoma, Transitional Cell, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.